TScan Therapeutics, Inc. Common Stock

TCRXNASDAQ • USD
0.14 USD
↘ 0.00 (1.45%)🟢LIVE (AS OF 11:54 AM EST)
🟢Market: OPEN

Shares of TScan Therapeutics, Inc. Common Stock (TCRX) are trading at $0.14. The stock presents a bearish profile across the board: technical indicators signal "Sell" and our fundamental models agree with a "Sell" rating. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 2/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest TCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$0.15
High?$0.17
Low?$0.14
Prev. Close?$0.15
Volume?141.0K
Avg. Volume?537.8K
VWAP?$0.15
Rel. Volume?0.26x
Bid / Ask
Bid?$0.14 × 500
Ask?$0.17 × 100
Spread?$0.03
Midpoint?$0.15
Valuation & Ratios
Market Cap?10.2M
Shares Out?63.5M
Float?55.3M
Float %?87.2%
P/E Ratio?N/A
P/B Ratio?0.27
EPS?-$1.70
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Employees
142
Market Cap
10.9M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2021-07-16
Address
830 WINTER STREET
WALTHAM, MA 02451
Phone: 857-399-9500
Technical OutlookSell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
12
Z-Score?
0
Momentum?
23
Short Sent.?
74
Piotroski F-Score?2/9Weak
Altman Z-Score?-8.20Distress
Confidence?49%Low
Full Fundamental Analysis →
Short InterestModerate
Short % of Float?3.65%Low
Short Interest?2.0M
Days to Cover?4.7
Free Float55.3M
Avg Daily Volume432.9K
Settlement Date2026-10-30
Financial Health
Current Ratio?2.03Strong
Quick Ratio?2.03Strong
Cash Ratio?1.93Strong
Debt/Equity?0.87Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.27CHEAP▾
P/S?
Peers
100
S&P
67
1.96CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
Peers
100
S&P
97
0.3CHEAP▾
EV/Sales?
S&P
97
-5.77CHEAP▾
Returns & Efficiency
ROE?
S&P
3
-302.8%WEAK▾
ROA?
S&P
3
-81.4%WEAK▾
Cash Flow & Enterprise
FCF?$-111268000
Enterprise Value?$-29899112
Fundamentals ratios updated end of day